Kathie M. Bishop
Acadia Pharmaceuticals (United States)(US)ABS Consulting (United States)(US)
Publications by Year
Research Areas
Neurogenetic and Muscular Disorders Research, Genetics and Neurodevelopmental Disorders, Autism Spectrum Disorder Research, Family and Disability Support Research, Nerve injury and regeneration
Most-Cited Works
- → Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy(2017)2,217 cited
- → Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy(2018)1,401 cited
- → Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study(2016)1,008 cited
- → An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study(2013)603 cited
- → Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy(2016)595 cited
- → Regulation of Area Identity in the Mammalian Neocortex by Emx2 and Pax6(2000)576 cited